Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Robinson, Cleo ^a,b   Alfonso, Helman ^c   Woo, Samantha ^a   Walsh, Amy ^a   Olsen, Nola ^d   Musk, Arthur W ^d,e   Robinson, Bruce W S ^a   Nowak, Anna K ^a   Lake, Richard A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Anatomical Pathology   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; ATORVASTATIN; CERIVASTATIN; CROCIDOLITE; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUSTRALIA; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; LATENT PERIOD; MALE; MESOTHELIOMA; MOUSE; NONHUMAN; SYMPTOMATOLOGY; ADULT; AGED; ANIMAL; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; TRANSGENIC MOUSE;

ADULT; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASBESTOS; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MICE; MICE, TRANSGENIC; MIDDLE AGED; PYRROLES;

EID: 84905460215     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103025     Document Type: Article

References (35)

1. Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353(15): 1591-1603. (Pubitemid 41434638)
2. Olsen NJ, Franklin PJ, Reid A, de Klerk NH, Threlfall TJ, et al. (2011) Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust 195(5): 271-274.
3. Gonzalez CA (2006) Nutrition and cancer: the current epidemiological evidence. Br J Nutr 96 Suppl 1: S42-45.
4. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, et al. (2005) Statins and the risk of colorectal cancer. N Engl J Med 352(21): 2184-2192. (Pubitemid 40727085)
5. Mamede AC, Tavares SD, Abrantes AM, Trindade J, Maia JM, et al. (2011) The role of vitamins in cancer: a review. Nutr Cancer 63(4): 479-494.
6. Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13(5): 518-527.
7. Hanahan D,Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646-674.
8. Shureiqi I, Reddy P, Brenner DE (2000) Chemoprevention: general perspective. Crit Rev Oncol Hematol 33(3): 157-167. (Pubitemid 30163069)
9. Robinson C, Woo S, Walsh A, Nowak AK, Lake RA (2012) The antioxidants vitamins A and E and selenium do not reduce the incidence of asbestos-induced disease in a mouse model of mesothelioma. Nutr Cancer 64(2): 315-322.
10. Robinson C, Woo S, Nowak AK, Lake RA (2014) Dietary Vitamin D Supplementation Does Not Reduce the Incidence or Severity of Asbestos-Induced Mesothelioma in a Mouse Model. Nutr Cancer.
11. Alfonso HS, Reid A, de Klerk NH, Olsen N, Mina R, et al. (2010) Retinol supplementation and mesothelioma incidence in workers earlier exposed to blue asbestos (Crocidolite) at Wittenoom, Western Australia. Eur J Cancer Prev 19(5): 355-359.
12. Robinson C, Walsh A, Larma I, O'Halloran S, Nowak AK, et al. (2011) MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma. Eur J Cancer 47(1): 151-161.
13. Robinson C, Alfonso H, Woo S, Olsen N, Musk AW, et al. (2014) NSAIDS and COX-2 inhibitors do not reduce the incidence nor severity of asbestos-induced mesothelioma: evidence from an animal model and a human cohort. submitted.
14. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancerrelated mortality. N Engl J Med 367(19): 1792-1802.
15. Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, et al. (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 7(1): e29849.
16. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5(12): 930-942. (Pubitemid 41766782)
17. Hoque A, Chen H, Xu XC (2008) Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 17(1): 88-94. (Pubitemid 351196277)
18. Bu DX, Griffin G, Lichtman AH (2011) Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 22(3): 165-170.
19. Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, et al. (1998) Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med 157(5 Pt 1): 1616-1622.
20. Riganti C, Orecchia S, Pescarmona G, Betta PG, Ghigo D, et al. (2006) Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int J Cancer 119(1): 17-27.
21. de Klerk NH, Musk AW, Ambrosini GL, Eccles JL, Hansen J, et al. (1998) Vitamin A and cancer prevention II: comparison of the effects of retinol and beta-carotene. Int J Cancer 75(3): 362-367. (Pubitemid 28100036)
22. Robinson C, van Bruggen I, Segal A, Dunham M, Sherwood A, et al. (2006) A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res 66(22): 10786-10794. (Pubitemid 44876974)
23. Musk AW, de Klerk NH, Ambrosini GL, Eccles JL, Hansen J, et al. (1998) Vitamin A and cancer prevention I: observations in workers previously exposed to asbestos at Wittenoom, Western Australia. Int J Cancer 75(3): 355-361. (Pubitemid 28100035)
24. Nicholson WJ, Raffn E (1995) Recent data on cancer due to asbestos in the U.S.A. and Denmark. Med Lav 86(5): 393-410. (Pubitemid 26037064)
25. Mant A, Lowinger J, Hall W, Whicker S, Ringland C, et al. (2007) Statins down under. Br J Clin Pharmacol 63(1): 125-127.
26. Musk AW, Olsen N, Alfonso H, Reid A, Mina R, et al. (2011) Predicting survival in malignant mesothelioma. Eur Respir J 38(6): 1420-1424.
27. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama 301(1): 39-51.
28. The Alpha-Tocopherol BCCPSG (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330(15): 1029-1035.
29. Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118. (Pubitemid 40261799)
30. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30(7): 609-641. (Pubitemid 39451828)
31. Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjorge T, et al. (2013) Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One 8(1): e54242.
32. Xiao H, Yang CS (2008) Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer 123(5): 983-990.
33. Beales IL, Vardi I, Dearman L (2012) Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 24(8): 917-923.
34. Coogan PF, Kelly JP, Strom BL, Rosenberg L (2010) Statin and NSAID use and prostate cancer risk. Pharmacoepidemiol Drug Saf 19(7): 752-755.
35. Zhou P, Cheng SW, Yang R, Wang B, Liu J (2012) Combination chemoprevention: future direction of colorectal cancer prevention. Eur J Cancer Prev 21(3): 231-240.